Bone Therapeutics SA appointed Lieve Creten as an interim CFO, effective 21 September 2021. Lieve Creten succeeds Jean-Luc Vandebroek, who will continue to serve as Board member and will assist in the transition process. Bone Therapeutics appointed Lieve Creten for her large experience in management, finance reporting and business deals including acquisitions or mergers for both public and private companies as the company strategically realigns to fully focus on its iMSC cell and gene therapy platform of professional mesenchymal stromal cells (MSCs) for a wider range of therapeutic targets. Lieve’s extensive financial experience gained at Deloitte Financial Advisory Belgium as a certified public accountant will be deployed to ensure optimal financial control, oversight and compliance during Bone Therapeutics strategic refocus on the iMSC platform, which includes its product ALLOB.